| Inducible apoptosis as a safety switch for adoptive cell therapy A Di Stasi, SK Tey, G Dotti, Y Fujita, A Kennedy-Nasser, C Martinez, ... New England Journal of Medicine 365 (18), 1673-1683, 2011 | 1701 | 2011 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood, The Journal of the American Society of Hematology 122 (17), 2965-2973, 2013 | 621 | 2013 |
| Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell … AM Leen, A Christin, GD Myers, H Liu, CR Cruz, PJ Hanley, ... Blood, The Journal of the American Society of Hematology 114 (19), 4283-4292, 2009 | 379 | 2009 |
| Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral … PJ Hanley, CRY Cruz, B Savoldo, AM Leen, M Stanojevic, M Khalil, ... Blood, The Journal of the American Society of Hematology 114 (9), 1958-1967, 2009 | 293 | 2009 |
| Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells SH Huang, Y Ren, AS Thomas, D Chan, S Mueller, AR Ward, S Patel, ... The Journal of clinical investigation 128 (2), 876-889, 2018 | 208 | 2018 |
| Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma CM Bollard, T Tripic, CR Cruz, G Dotti, S Gottschalk, V Torrano, ... Journal of clinical oncology 36 (11), 1128-1139, 2018 | 177 | 2018 |
| Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma J Cano-Mejia, RA Burga, EE Sweeney, JP Fisher, CM Bollard, ... Nanomedicine: Nanotechnology, Biology and Medicine 13 (2), 771-781, 2017 | 135 | 2017 |
| Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes S Naik, SK Nicholas, CA Martinez, AM Leen, PJ Hanley, SM Gottschalk, ... Journal of Allergy and Clinical Immunology 137 (5), 1498-1505. e1, 2016 | 132 | 2016 |
| SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein MD Keller, KM Harris, MA Jensen-Wachspress, VV Kankate, H Lang, ... Blood, The Journal of the American Society of Hematology 136 (25), 2905-2917, 2020 | 131 | 2020 |
| Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma U Gerdemann, U Katari, AS Christin, CR Cruz, T Tripic, A Rousseau, ... Molecular therapy 19 (12), 2258-2268, 2011 | 131 | 2011 |
| Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma ES Yvon, R Burga, A Powell, CR Cruz, R Fernandes, C Barese, T Nguyen, ... Cytotherapy 19 (3), 408-418, 2017 | 126 | 2017 |
| CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo PJ Hanley, JJ Melenhorst, S Nikiforow, P Scheinberg, JW Blaney, ... Science translational medicine 7 (285), 285ra63-285ra63, 2015 | 119 | 2015 |
| Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience CR Cruz, PJ Hanley, H Liu, V Torrano, YF Lin, JA Arce, S Gottschalk, ... Cytotherapy 12 (6), 743-749, 2010 | 114 | 2010 |
| Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4 CR Cruz, U Gerdemann, AM Leen, JA Shafer, S Ku, B Tzou, TM Horton, ... Clinical Cancer Research 17 (22), 7058-7066, 2011 | 106 | 2011 |
| The growth hormone secretagogue receptor CRY Cruz, RG Smith Vitamins & Hormones 77, 47-88, 2007 | 81 | 2007 |
| Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma JA Shafer, CR Cruz, AM Leen, S Ku, A Lu, A Rousseau, HE Heslop, ... Leukemia & lymphoma 51 (5), 870-880, 2010 | 74 | 2010 |
| Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study AB Hont, CR Cruz, R Ulrey, B O’Brien, M Stanojevic, A Datar, S Albihani, ... Journal of Clinical Oncology 37 (26), 2349-2359, 2019 | 73 | 2019 |
| Engineering the TGFβ receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma RA Burga, E Yvon, E Chorvinsky, R Fernandes, CRY Cruz, CM Bollard Clinical Cancer Research 25 (14), 4400-4412, 2019 | 69 | 2019 |
| Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein–Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation PJ Hanley, DR Shaffer, CRY Cruz, S Ku, B Tzou, H Liu, ... Cytotherapy 13 (8), 976-986, 2011 | 68 | 2011 |
| Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer S Patel, RA Burga, AB Powell, EA Chorvinsky, N Hoq, SE McCormack, ... Frontiers in oncology 9, 196, 2019 | 66 | 2019 |
